Guidance, NICE advice and quality standards In development

Skip to filters Skip to results

Showing 351 to 372 of 372

Sort by

Type: GuidanceRemove Type: Guidance filter

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]	Technology appraisal guidance	TBC
Urinary Tract Infection (recurrent): antimicrobial prescribing	NICE guideline	13 November 2024
Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease [ID3821]	Technology appraisal guidance	20 November 2024
Vamorolone for treating Duchenne muscular dystrophy [ID4024]	Technology appraisal guidance	TBC
Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]	Technology appraisal guidance	TBC
Venetoclax with azacitidine for untreated high-risk myelodysplastic syndromes [ID6314]	Technology appraisal guidance	TBC
Venetoclax with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma ID1565	Technology appraisal guidance	TBC
Venetoclax with dexamethasone for treating relapsed or refractory t(11;14)-positive multiple myeloma after lenalidomide and a proteasome inhibitor [ID4040]	Technology appraisal guidance	TBC
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) are suitable [ID6291]	Technology appraisal guidance	TBC
Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]	Technology appraisal guidance	TBC
Vibegron for treating symptoms of overactive bladder ID6300	Technology appraisal guidance	TBC
Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]	Technology appraisal guidance	TBC
Voxelotor for treating sickle cell disease [ID1403]	Technology appraisal guidance	12 June 2024
VTS-270 for treating Niemann-Pick type C1 [ID1267]	Highly specialised technology	TBC
Waldenstrom's macroglobulinaemia - ibrutinib [ID884]	Technology appraisal guidance	22 November 2017
Women's and reproductive health guidelines	NICE guideline	TBC
Zanubrutinib for treating relapsed or refractory mantle cell lymphoma after 1 or more treatments [ID6392]	Technology appraisal guidance	TBC
Zanubrutinib for treating relapsed or refractory marginal zone lymphoma [ID5085]	Technology appraisal guidance	17 July 2024
Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079]	Technology appraisal guidance	TBC
Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008]	Technology appraisal guidance	7 August 2024
Zio XT for detecting cardiac arrhythmias	Medical technologies guidance	TBC
Zolbetuximab with chemotherapy for untreated claudin 18.2-positive HER2 negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma [ID5123]	Technology appraisal guidance	23 October 2024

Results per page

10
25
50
All